3Constantin N. Baxevanis,Panagiota A. Sotiropoulou,Nectaria N. Sotiriadou,Michael Papamichail. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy[J] 2004,Cancer Immunology, Immunotherapy(3):166～175 被引量：1
二级参考文献27
1[1]Schnitt SJ.Breast cancer in the 21st century: neu opportunities and neu challenges[J].Mod Pathol,2001;14(3):213-218. 被引量：1
2[2]Karunagaran D,Tzahar E,Beerli RR,et al.ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer[J].EMBO J,1996;15(2):254-264. 被引量：1
3[3]Ross JS,Fletcher JA.The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy[J]. Oncologist,1998;3(4):237-252. 被引量：1
4[4]Yamauchi H,Stearns V,Hayes DF.When is a tumor marker ready for prime time?A case study of c-erbB-2 as a predictive factor in breast cancer[J].J Clin Oncol,2001;19(8):2334-2356. 被引量：1
5[5]Pegram MD,Lipton A,Hayes DF,et al.Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment[J].J Clin Oncol,1998;16(8):2659-2671. 被引量：1
6[6]Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J Clin Oncol,1999;17(9):2639-2648. 被引量：1
7[7]Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001;344(11):783-792. 被引量：1
8[8]Tanner M,Gancberg D, Di Leo A,et al.Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples[J].Am J Pathol,2000;157(5):1467-1472. 被引量：1
9[9]Cell Markers And Cytogenetics Committees College Of American Pathologists.Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing[J].Arch Pathol Lab Med,2002;126(7):803-808. 被引量：1
10[10]Miles DW.Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting[J].Breast Cancer Res,2001;3(6):380-384. 被引量：1
